References
- Porter, ME. What is value in health care? N Engl J Med 2010;363:2477-81
- VanLare JM, Conway PH. Value-based purchasing – national programs to move from volume to value. N Engl J Med 2012;367:292-5
- Burwell SM. Setting value-based payment goals – HHS efforts to improve U.S. health care. N Engl J Med 2015;372:897-9
- Thomson S, Sharing L, Charenew ME. Value-based cost sharing from the United States and elsewhere can increase patients’ use of high-value goods and services. Health Aff (Millwood) 2013;32:704-12
- Berwick DM, Nolan TW, Whittington J. The triple aim: care, health, and cost. Health Affairs 2008;27:759-69
- Langley PC. Recent developments in the health technology assessment process. In: Fulda TR, Wertheimer AI, eds. Handbook of pharmaceutical public policy. New York: Pharmaceutical Products Press, 2007
- WellPoint. Health technology assessment guidelines: drug submission guidelines for new products, new indications and new formulations (V 2.0). West Hills, CA: Wellpoint Next Rx, 2007
- WellPoint. Health technology assessment guidelines: drug submission guidelines for re-evaluation of products, indications and formulations (v 2.0). West Hills, CA: WellPoint Next Rx, 2007
- WellPoint. Health technology assessment guidelines: evidentiary and analytical standards in health technology assessments (V 2.0). West Hills, CA: WellPoint Next Rx, 2007
- Sweet B, Tadlock CG, Waugh W, et al. The WellPoint outcomes based formulary: enhancing the health technology assessment process. J Med Econ 2005;8:13-25
- Centers for Disease Control and Prevention. “Framework for Program Evaluation in Public Health”. MMWR 1999;48:1-40
- U.S. Department of Health and Human Services. Centers for Disease Control and Prevention. Office of the Director, Office of Strategy and Innovation. Introduction to program evaluation for public health programs: a self-study guide. Atlanta, GA: Centers for Disease Control and Prevention, 2005
- Huserau, D, Drummond, M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement. Value Health 2013;16:e1-5
- Academy of Managed Care Pharmacy. The AMCP format for formulary submissions, version 3.1. Alexandria, VA: Academy of Managed Care Pharmacy, 2012. http://www.amcp.org/practice-resources/amcp-format-formulary-submisions/. Accessed 20 September 2015
- Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health 2014;17:5-14
- Caro JJ, Briggs AH, Siebert U, et al. Modeling good research practices – Overview: a report of the ISPOR-SMDM Modeling Good Practices Task Force-1. Value Health 2012;15:796-803
- Eddy DM, Hollingworth W, Caro JJ, et al. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Value Health 2012;15:843-50
- Langley P. Validation of modeled pharmacoeconomic claims in formulary submissions. J Med Econ 2015; 18(12): 993-999
- Drummond ML, Sculpher MJ, Torrance GM, et al. Methods for the economic evaluation of health care programmes, 3rd edn. Oxford: OUP, 2005
- Simatupang Togar M, Ramaswami Sridharan R. An integrative framework for supply chain collaboration. Int J Log Manage 2005;16:257-74
- Wasser T, Haynes K, Barron J, Cziraky M. Using big data to validate claims made in the pharmaceutical approval process. J Med Econ 2015;18(12): 1013-1019
- Lawrence TB, Hardy C, Phillips N. Institutional effects of interorganizational collaboration: the emergence of proto-institutions. Acad Manage J 2002;45:281-90
- Savage GT, Bunn MD, Gray B, et al. Stakeholder collaboration: implications for stakeholder theory and practice. J Bus Ethics 2010;96:21-6
- Jamal TB, Getz D. Collaboration theory and community tourism planning. Ann Tourism Res 1995;22:186-204